- Posts tagged yaz trials
- Explore yaz trials on posterous
Yaz Lawsuits Number Over 7,000
More than seven thousand plaintiffs across the country have filed lawsuits against Bayer Pharmaceuticals, the manufacturers of the popular birth control pill Yaz. Yaz is a fourth generation drospirenone-based oral contraceptive, which was introduced on the market in 2006 and since then has remained one of the most popular forms of birth control in the country, especially amongst teenaged girls. However, it comes with complications.
Yaz patients have experienced side effects that range from serious to potentially fatal – gallbladder disease, stroke, heart attack, pulmonary embolism, deep vein thrombosis, and problems with blood clots are all among the laundry list of side effects that Yaz has afflicted countless patients with. It is no surprise, then, that many of them are filing suit against the company responsible for the production and distribution of such a product – women are demanding compensation for past and future medical bills related to their side effects, and bereaved families are filing wrongful death lawsuits.
Yaz litigation has been combined into a multidistrict case, which would normally speed up the legal process by combining pretrial processes of similar cases in order to speed up litigation. However, conflicts have prevented Yaz multidistrict litigation from being as efficient as possible – connections between state and federal courts have dissolved, and lawyers from both sides of the case were involved in a debate as to whether or not foreign documents could be used as evidence.
The presiding judge, the Honorable David Herndon, has appointed a special master to help mediate these issues in order to speed up the litigation process. No Yaz trials in the multidistrict litigation case have yet gone to trial, but preliminary bellwether trials could take place as early as the beginning of next year. These trials will set the tone for the remainder of Yaz litigation and will give plaintiffs a good idea of how much compensation they can expect from the German-based pharmaceuticals giant.

